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Introduction 
The existence of a surface active substance in the 
lung was first postulated by von Neergard as early as 
1929 (1). He found the calculated surface tension at 
the alveolar air-liquid interface to be too high to 
prevent end-expiratory alveolar collapse and 
atelectasis. Therefore, he predicted the presence of an 
agent able to exert and maintain a low alveolar 
surface tension in order to guarantee adequate 
alveolar ventilation throughout the respiratory cycle. 
Thirty years later, Pattle (2) and Clements (3) 
found a substance in lung oedema fluid and lung 
extracts that indeed lowered surface tension dramati- 
cally. The material was found to be composed of a 
phospholipid and a protein fraction and was termed 
surfactant (surface active agent). 
In 1959, Avery and Mead (4) established the role 
of a surfactant deficit in hyaline membrane disease 
of premature infants, now commonly called infant 
respiratory distress syndrome (IRDS). 
Since this pioneering work, the understanding of 
the pulmonary surfactant system has grown exponen- 
tially. The alveolar type II cell has been identified as 
the site of alveolar surfactant synthesis. The precise 
composition of the material is now known down to 
the genetic codes of surfactant specific proteins. 
Many details concerning surfactant synthesis and 
secretion and its regulation and metabolism have 
been elucidated. Surfactant replacement therapy is 
established as a routine life-saving therapy in IRDS 
[e.g. (5)]. Cumulating evidence strongly suggests that 
a surfactant dysfunction contributes to the morbidity 
and mortality of the adult respiratory distress syn- 
drome (ARDS) which can probably be ameliorated 
by substitution therapy. 
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In recent years, surfactant functions other than the 
maintenance of normal lung function have evolved. 
Perhaps most important among these findings is that 
surfactant seems to play a role in pulmonary defence 
mechanisms and local immunomodulation. There- 
fore, the role of surfactant in various lung diseases is 
attracting growing attention. 
The purpose of this article is to review the current 
knowledge on the surfactant system with special 
emphasis on clinical implications and perspectives for 
the diagnosis and treatment of adult respiratory 
disorders. 
Surfactant Composition 
Surfactant is a unique and complex mixture of 
lipids and proteins (Fig. 1). Its extracellular pool 
size has been investigated in animals and seems to 
range between about 10 and 15 mg kg-’ body 
weight in adults. Mature newborns have 5- to IO-fold 
higher values (6). Assuming similar values in man, a 
70 kg person would have an estimated alveolar sur- 
factant pool of approximately 0.7-1.0 g. According 
to other authors (7), the calculated surfactant con- 
centration of the alveolar lining layer in the normal 
adult lung is approximately 120 mg ml - ‘. Assuming 
an alveolar surface area of 100 m2 with a surfactant 
concentration of 50~1 rn-‘, the total alveolar sur- 
factant volume would thus approximate 5 ml, or 
600 mg. However, there are as yet no available data 
on the normal range of the alveolar surfactant pool in 
man. 
SURFACTANT LIPIDS 
Lipids are the major surfactant component by 
weight (Fig. 1). They make up about X5-90% of 
whole isolated surfactant (8,9). Approximately 90% 
of this lipid fraction consists of a mixture of 
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Surfactant Composition 
2.0% SP-A+B+C+D 
5.0% Other lipids A 
17.0% Unsaturated PC 
50.0% Saturated .PC 
Fig. I Composition of isolated whole surfactant from bronchoalveolar lavage (approximate percentage of total weight). 
PC. Phosuhatidvlcholine: PG. Phosohatidvlalvcerol: PE, Phosphatidylethanolamine; PI, Phosphatidylinositol; Sph, 
Sphingomyelin; PL, Phospholipids; SP, Surfac~ant protein. 
phospholipids. The remaining 10% are composed of 
other lipids, mainly cholesterol. Phospholipids com- 
bine lipophilic and hydrophilic properties and pos- 
sess the ability to achieve low surface tensions when 
lining air-liquid interfaces. 
The phospholipid composition of human lung sur- 
factant is shown in Fig. 1. None of these phospho- 
lipids are unique to surfactant, but the composition 
differs from phospholipid profiles in other organs, 
e.g. the relative concentrations of phosphatidyl- 
choline and phosphatidylglycerol are higher. 
Phosphatidylcholine accounts for approximately 
80% of total surfactant phospholipids and for about 
two-thirds of whole surfactant. Approximately 70% 
of its fatty acids are saturated under normal con- 
ditions (S), the most common saturated acid being 
palmitic acid. Dipalmitoyl-phosphatidylcholine 
(DPPC) is the surfactant component which is pre- 
dominantly responsible for the reduction of alveolar 
surface tension (10,ll). Its hydrophilic (choline) 
residue associates with the alveolar liquid phase while 
the hydrophobic (palmitic acid) residue reaches into 
the air phase (12). 
SURFACTANT PROTEINS 
By weight, the total protein portion accounts for 
approximately 10% of whole isolated surfactant. 
Roughly 80% of these proteins are contaminating 
serum proteins and only 20% are surfactant-specific 
(Fig. 1). 
Four surfactant-specific proteins (SP) have been 
identified to date. The first three proteins are simply 
termed Surfactant Protein A, B and C in descending 
rank of their molecular masses (13). More recently, 
a fourth protein, SP-D has been described (14) 
(Table 1). 
Surfactant Protein A 
Surfactant Protein A is the most abundant sur- 
factant protein in the alveolar space. In vivo, it is 
found as a group of isoforms with a molecular weight 
of approximately 26-38 kDa in the reduced state, 
depending on the extent of post-translational modi- 
fications (15,16). Its Clterminal domain has struc- 
tural and functional homologies with C-type lectins. 
In addition, it contains a collagen-like domain (17) 
which is the probable association site of SP-A 
monomeres. After alveolar secretion, native SP-A is 
predominantly found as a hexamer with trimeric 
subunits of polypeptide chains, thus forming an 
18-merit structure resembling a ‘flower bouquet’ (18). 
Surfactant Protein A seems to play an important 
role in the formation of tubular myelin, a transitory 
surfactant structure which is found immediately after 
alveolar secretions (19-21). As with SP-B and SP-C, 
SP-A probably enhances the surface activity of the 
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Table I Some characteristics of the surfactant-specific proteins 
Molecular 






0 Lectin/collagen hybrid Supports alveolar macrophage activities and 
regulates surfactant secretion 
+++ Disulphide bridges Optimizes surface activity 
++++ Rich in hydrophobic valine Optimizes surface activity 
0 Lectiu/collagen hybrid Interacts with alveolar macrophages and 
regulates surfactant secretion 
mature surfactant layer (22). However, the relevance 
of SP-A regarding this aspect seems small and is still 
a matter of debate (23,24). 
The structural homologies of SP-A and lectins 
stimulated investigations of possible common bio- 
logical functions of these proteins. Indeed, it could be 
demonstrated that the presence of SP-A enhances the 
phagocytosis of opsonized sheep erythrocytes by 
macrophages and monocytes in a concentration- 
dependent manner (25). Furthermore, SP-A is able to 
increase the phagocytosis of Staphylococcus aureus 
(26,27), Escherichia coli, Pseudomonas aeroguinosa 
(27), Herpes simplex virus type 1 (28) and colloidal 
gold particles (22). Recently, it has been shown that 
SP-A binds to Influenza A viruses via its sialic acid 
residues and has the ability to neutralize the virus 
(29). Moreover, SP-A also binds to Herpes simplex 
virus type-l infected cells (30). Interestingly, a 
120 kDa glycoprotein covering the surface of 
Pneumocystis carinii has recently been identified 
which is a ligand for the carbohydrate binding 
domain of SP-A (31). The SP-A binding capacity of 
P. carinii possibly interferes with the recognition and 
phagocytosis of this micro-organism by alveolar 
macrophages (32) (see ‘Pneumonia’). Recently, it has 
also been shown that SP-A promotes attachment of 
Mycobacterium tuberculosis to alveolar macrophages 
during HIV-infection (33). 
Another function of SP-A is to maintain the 
homeostasis between intracellular and extracellular 
surfactant pools (24). In vitro, SP-A blocks the 
secretion of phosphatidylcholine from cultured 
alveolar type II cells (34) by feedback inhibition. It 
also enhances the type II cell uptake of surfactant 
lipids (35). These effects are probably mediated by 
a type II cell SP-A receptor. Recently, an SP-A 
recognition protein (SPAR) has been identified in 
type II cell membranes which is believed to serve as 
such a receptor or, at least, represents a portion of 
it (36). 
Surfactant Protein B 
Surfactant Protein B is a small protein with a 
molecular weight of approximately 8-9 kDa under 
reducing conditions (37,38). Although it is very 
hydrophobic, it remains soluble in aqueous solutions 
to some extent. Surfactant Protein B forms thiol- 
dependent oligomers of different sizes with the dimer 
being the most common form in vivo (39,40). It 
possesses no known immunomodulatory or regulat- 
ory function but seems to be a key protein for the 
formation of a functionally optimal and stable 
surfactant layer on the alveolar surface (4143) as 
well as for the formation of tubular myelin (20). 
Congenital lack of SP-B expression leads to severe 
impairment of lung function and subsequently to 
respiratory failure (44), demonstrating the vital 
importance of this surfactant protein. The amino 
acid sequence of SP-B contains high amounts of 
cysteine, suggesting that disulphide bridges may be 
important to the role of this protein in the surfactant 
complex (15). Indeed, intramolecular disulphide 
bridges seem to contribute to the structural proper- 
ties of the SP-B polypeptide chain, and an inter- 
molecular disulphide link explains the frequent 
natural occurrence of SP-B dimers (39). Further- 
more, SP-B has a strong positive net charge (at 
physiological pH) which seems to be important to the 
interaction between SP-B and the anionic phospho- 
lipids (39,43). However, the structural interaction 
between SP-B and other surfactant components is 
very complex and still needs to be more clearly 
defined. 
Surfactant Protein C 
Surfactant Protein C is a very small protein with 
a molecular weight of approximately 45 kDa 
(reduced). It is extremely hydrophobic which is partly 
due to a high content of the hydrophobic amino acid, 
valine (13,16,38), and is therefore only soluble in 
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organic solvents. Its small size, hydrophobicity and 
low immunogenicity make the investigation of this 
protein a difficult task. Surfactant Protein C prob- 
ably has no role in tubular myelin formation (20). As 
far as its functional role in the surfactant complex is 
presently understood, it contributes to the formation 
and stabilization of the alveolar, surfactant mono- 
layer in conjunction with SP-B (42). Post- 
translational palmitoylation of SP-C appears to be 
important both for its optimal function and its 
contribution to the resistance of the surfactant com- 
plex against potential surfactant inhibitors (16,45). 
The molecular structure and most of the properties of 
SP-C are substantially different from SP-B, suggest- 
ing that both proteins have separate roles in the 
surfactant complex. Indeed, in vitro studies indicate 
that SP-C may be more important to the adsorption 
of phospholipids, while SP-B supports the reduction 
of surface tension more effectively (46). There seem to 
be no structural similarities of SP-C to other pro- 
teins of known functions which would suggest an 
additional role of SP-C (40). 
Surfactant Protein D 
Surfactant Protein D is a collagenous glycoprotein 
which is synthesized by alveolar type II cells (14,47), 
but it has also been identified in Clara cells (48,49). 
There is an ongoing debate as to whether this protein 
is a true surfactant component or a protein that is 
only loosely and functionally associated with the 
surfactant complex. In rat bronchoalveolar lavage 
fluids, the total SP-D content was found to be 
approximately 12% of that of SP-A (50). Surfactant 
Protein D has a molecular size of approximately 
43 kDa (reduced) and appears to aggregate to 
12-merit complexes in vivo. Surfactant Protein D has 
certain structural and biophysical similarities to 
SP-A, but it is probably even more readily soluble in 
the aqueous alveolar milieu. Like SP-A, SP-D does 
not seem to have a relevant role in the surface activity 
of the surfactant layer (47), and as with SP-A, is 
probably involved in stimulating alveolar macro- 
phages. Structural analogies to C-type lectins such as 
mannose-binding protein, conglutinin and SP-A 
suggest just such a role in local host defence (51,52). 
Recently, for example, it has been shown (53) that 
SP-D binds to E. coli in a time- and dose-dependent 
manner. Furthermore, SP-D enhances the produc- 
tion of oxygen radicals by alveolar macrophages (54). 
Another recent study indicates that SP-D may have a 
regulatory function for alveolar type II cells by 
counteracting the inhibitory effects of SP-A on phos- 
pholipid secretion (55). 
Plate I Transmission electron microscopy view of a alveo- 
lar type II cell (approx. x 9300). Note the large round 
nucleus and several lamellar bodies in the cytoplasm. 
Morphology and Ultrastructure 
The site of alveolar surfactant synthesis and secre- 
tion is the cuboidal alveolar type II cell. These cover 
less than 5% of the alveolar surface, but comprise 
about 15% of the total cell number found in the adult 
human lung (56). There is evidence to suggest that 
surfactant synthesis and secretion in the respiratory 
tract is not exclusively restricted to the alveolar type 
II cell, but that it may also take place in higher 
airways to a small degree, for instance in Clara cells 
(48,49,57,58) and possibly even in tracheal epithelium 
(59) and the middle ear (60). 
The alveolar surfactant components are synthe- 
sized and assembled in the endoplasmic reticulum of 
type II cells and are then transferred to the Golgi 
apparatus prior to forming so-called lamellar bodies 
in the cytoplasm (Plate 1). Immunocytochemistry 
and autoradiography techniques allow detailed 
examination of these processes (61). Mature lamellar 
bodies are eventually transported into the alveolar 
space by merocrine secretion. Here, they are rapidly 
transformed into tubular myelin, a short-lived struc- 
ture composed of a lattice of highly ordered tubules. 
Surfactant Protein A plays a role in the formulation 
of tubular myelin and has been located at the corners 
of the tubular framework by immune electron micro- 
scopic techniques (19). An in vitro study (20) suggests 
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that in addition to SP-A, the presence of SP-B is 
necessary for tubular myelin formation. Finally, the 
material is spread on the alveolar surface to form the 
mature surfactant layer. 
Synthesis, Metabolism, and Regulation 
Pulmonary surfactant undergoes a continuous 
dynamic process of synthesis and degradation which 
will only be briefly outlined here (for more details see 
(40,62-67,92). 
Basically, all phospholipid components of sur- 
factant are synthesized and incorporated into the 
lamellar bodies within the alveolar type II cell. 
Dipalmitoyl-phosphatidylcholine is the best studied 
phospholipid regarding intracellular synthesis path- 
ways. It is de nova synthesized from blood-derived 
phospholipid precursors and from recycled material 
after re-entry from the alveolar space (65,68). 
In the alveolar region, gene expression for SP-A is 
restricted to the alveolar type 11 cell as shown by 
in situ hybridization (69). It is synthesized as a pre- 
protein followed by a variety of post-translational 
modifications like sialylation, acetylation and sul- 
phation (13,16). Surfactant Protein A monomeres 
are oligomerized to 18-merit ‘llower bouquet’-like 
structures (18). 
Surfactant synthesis has been found to be 
influenced by a number of different stimuli (63). 
Glucocorticosteroids, adrenergic stimuli, CAMP, 
oestrogens and thyroid hormones have been 
described to enhance surfactant synthesis. However, 
the in vivo role and importance of these factors is not 
clearly determined. Some of these stimuli, e.g. gluco- 
corticoids, may vary in their effects depending on 
dose and time (70), and there may be different 
pathways for the regulation of surfactant phospho- 
lipid and protein synthesis (66). Recent evidence 
(71,72) has demonstrated that exogenous glucocorti- 
coids enhance surfactant protein synthesis and 
suggests that these hormones may have a role in the 
pulmonary response to stress. On the other hand, 
endogenous steroids under normal conditions do 
not seem to be important to baseline surfactant 
protein synthesis on the mRNA level but may, to 
a minor degree, contribute to translational or 
post-translational processing. 
Surfactant secretion into the alveolar space is 
accomplished by exocytosis of lamellar bodies. How- 
ever, it appears that they do not transport the full 
amount of all alveolar surfactant components. It 
seems likely that secretion of surfactant specific 
proteins like SP-A partially occurs via independent 
pathways (73). Experimental data suggest that 
various stimuli, including high volume lung inflation 
and increased ventilation rate, adrenergic agents, 
oestrogens and thyroid hormones, may enhance 
surfactant secretion, while P-receptor-blockade and 
an SP-A-dependent feedback circuit have inhibitory 
effects (8,61,64,74). Surfactant Protein D seems to 
counteract the inhibitory effect of SP-A on surfactant 
secretion (55). 
Turnover studies with labelled surfactant phos- 
pholipids have demonstrated alveolar half-lives of 
15-30 h (75,76). The fate of secreted surfactant 
material is determined by four mechanisms: 
(1) Recycling into the alveolar type II cell and other 
surrounding tissue; 
(2) Phagocytosis and. degradation by alveolar 
macrophages (67,77,78); 
(3) Intra-alveolar catabolism; and 
(4) Removal by the mucociliary escalator. 
Clearance studies in rabbits (79) have shown that 
approximately 7% of radiolabelled phosphatidyl- 
choline is removed via the upper airways within 
24 h, suggesting that this pathway is only of minor 
importance. Further work by the same group (80) 
provides evidence that most surfactant material is 
probably redistributed into the surrounding tissue 
or is recycled into alveolar type II cells. There is 
substantial evidence that surfactant phospholipid 
secretion and re-uptake is regulated at least in part by 
SP-A via a type II cell SP-A receptor (see ‘Surfactant 
Protein A’). 
Surfactant and Lung Function 
The tendency of the lung to reduce its volume is 
not only due to the elasticity of the lung parenchyma 
but, to a larger extent, due to the surface tension 
at the alveolar air-liquid interface (1,81). Surface 
tension may be defined as the energy that is necessary 
to overcome the attractive forces of molecules at an 
interface in order to increase a surface area, and is 
expressed in mN m - I. The surface tension in the 
alveolar space tends to reduce the alveolar surface 
area, i.e. it tends to keep the alveolar spaces small. 
Thus, it counteracts alveolar expansion during 
inspiration and supports alveolar retraction during 
expiration. The intra-alveolar pressure (P) is propor- 
tional to the surface tension (y) and inversely propor- 
tional to the alveolar radius (r). This is expressed by 
the law of Laplace: P=Zylr. 
The law allows the understanding of a number of 
dynamic changes throughout the ventilatory cycle. 
As an example, it demonstrates that the alveolar 
pressure increases when reducing the alveolar radius 
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at constant surface tension. Thus, the workload for 
alveolar expansion is increased in smaller alveoli. 
The surface tension at an ordinary water-air inter- 
face is approximately 72 mN m- ‘. The alveolar sur- 
factant material reduces the surface tension at the 
alveolar air-liquid interface, but not in a static, 
detergent-like manner. It is a unique property of this 
material that it influences the surface tension dynami- 
cally, that is, the degree of surface tension reduction 
is closely tuned to the alveolar radius. The surface 
tension is dynamically reduced with the expiratory 
decrease of the alveolar radius until it reaches plateau 
values below 10 mN m- ’ and then rises again .with 
the next inspiratory expansion. A glance at the law of 
Laplace shows that this surfactant effect is necessary 
to keep the alveolar pressure (P) constant throughout 
the ventilatory cycle. 
The most important surfactant component to 
accomplish the reduction of surface tension is satu- 
rated phosphatidylcholine. Other surfactant compo- 
nents like SP-A and, more important, SP-B and 
SP-C, enhance the surface activity of this phospho- 
lipid. The hydrophobic saturated fatty acids of satu- 
rated phosphatidylcholine are aligned in parallel and 
rise out of the liquid phase into the alveolar air. The 
hydrophilic choline residues are packed in the aque- 
ous phase of the alveolus. This arrangement remains 
stable throughout compression and extension of the 
alveolus, and reduces the strong alveolar cohesive 
forces. Thus, the respiratory workload is reduced 
throughout the respiratory cycle, lung compliance is 
improved, and alveolar collapse and atelectasis are 
prevented. 
Surfactant and Pulmonary Defence Mechanisms 
Surfactant material may contribute to pulmonary 
defence mechanisms and local immunomodulation in 
four different ways: 
(1) Support of non-specific defence mechanisms; 
(2) Direct host defence effects of surfactant 
components; 
(3) Immunomodulatory action on lymphocytes; and 
(4) Augmentation of alveolar macrophage activities. 
NON-SPECIFIC DEFENCE MECHANISMS 
Surfactant is part of the alveolar and bronchial 
epithelial lining fluid which is thought to act as a 
non-specific barrier against invasion and adhesion of 
micro-organisms. Also, surfactant has antioxidant 
activities (82) which may contribute to the protection 
of the alveolar epithelium by scavenging toxic 
(reduced) oxygen species. 
DIRECT HOST DEFENCE EFFECTS OF SURFACTANT 
COMPONENTS 
A few reports (8384) have addressed possible 
antibacterial properties of surfactant material. 
However, the results are conflicting and, therefore, 
possible antibacterial effects of surfactant remain 
controversial. 
Recently, it has been shown in vitro that SP-A 
binds to Influenza A viruses via its sialic acid residues 
and, thereby, neutralizes the virus (29). Another 
recent report suggests that SP-A promotes the attach- 
ment of M tubercul&s to alveolar macrophages 
during HIV-infection (33). However, this may be 
interpreted as an important early step towards the 
infection of host cells rather than a contribution to 
local host defence. Furthermore, SP-A binds to a 
120 kDa surface glycoprotein of P. carinii with high 
affinity (3 1). This SP-A binding capacity of P. car&ii 
may possibly interfere with the recognition and 
phagocytosis of this micro-organism by alveolar 
macrophages which normally utilize this ligand (32) 
(see ‘Pneumonia’). Thus, it seems that SP-A binding 
to micro-organisms does not effectively contribute to 
host defence mechanisms in all cases, 
SURFACTANT AND LYMPHOCYTE ACTIVITY 
Surfactant suppresses the activation and the pro- 
liferative response of lymphocytes to various stimuli 
in a dose-dependent manner (85-87). This suppressor 
activity is contained in the lipid fraction of surfactant 
(85). The major surfactant phospholipids, phosphati- 
dylcholine, phosphatidylglycerol and phosphatidyl- 
inositol, were shown to be responsible for this iminu- 
noregulatory effect. The nature of this effect has not 
yet been clarified but may be related to changes in 
lymphocyte cell membrane dynamics (88). Surfactant 
exerts its effects only on dormant lymphocytes or 
during the early stages of lymphocyte activation. In 
contrast, activated lymphocytes are not affected. The 
suppression appears to be largely irreversible, even 
after removal of surfactant material from the 
medium. These effects have been shown for a variety 
of lymphocyte activities such as proliferation, differ- 
entiation, immunoglobulin synthesis and natural 
killer cell activity (85-89). It may be hypothesized 
that these surfactant effects may protect the lungs 
from inappropriate immune reactions (16). 
SURFACTANT AND ALVEOLAR MACROPHAGE ACTIVITY 
Nearly all studies on the influence of surfactant on 
alveolar macrophage activity report an enhancement 
of macrophage functions. In detail, it has been shown 
that surfactant material supports phagocytosis 
(26,90) and intracellular killing (90,91) of S. aureus 
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and the phagocytosis of Herpes simplex virus type 1 
(28). It may also enhance the migration of alveolar 
macrophages (92) and their cytoxicity against tumour 
cells (93). 
Several studies (2.5,26,28) have shown that SP-A 
is responsible for the enhancement of alveolar 
macrophage functions. Probably, this effect is medi- 
ated by a macrophage receptor which binds SP-A. 
The specific binding and uptake of SP-A by macro- 
phages has been demonstrated by electron 
microscopy (78). Surfactant Protein A has also been 
shown to interact with M tuberculosis (33) and 
P. carinii (31,32). However, it seems doubtful if 
these phenomena effectively contribute to the clear- 
ance of these organisms by alveolar macrophages 
(see ‘Direct host defence effects of surfactant 
components’). 
Interestingly, surfactant preparations which lack 
SP-A inhibit production of proinflammatory 
cytokines such as interleukin-lj? and tumour necrosis 
factor-u by alveolar macrophages when stimulated 
by endotoxin or heat-killed S. aureus in vitro (94). 
In contrast to some of the findings outlined above, 
this study suggests immunosuppressive properties of 
SP-A-free surfactants on alveolar macrophages. 
Thus, the net effect of whole surfactant on alveolar 
macrophages in vivo is still debatable. 
ALVEOLAR TYPE n CELLS, CYTOKINES, AND CELL 
SIGNALLING PATHWAYS 
Type II pneumocytes have long been considered 
passive bystanders in alveolar immunologic processes 
and host defence mechanisms. However, recent evi- 
dence suggests that these cells may not only be 
involved in these processes via the effects of sur- 
factant components as outlined above, but they may 
also interact with local inflammatory processes via 
the production of mediators and the expression of 
surface antigens. 
Alveolar type II cells express a number of surface 
proteins which provide the basis for a direct cell-to- 
cell interaction with molecular structures on the 
membrane surface of leukocytes. For instance, type 
II cells obtained from normal lung specimens have 
been shown to express the adhesion molecules 
ICAM-1, the VLA-4a (CD49d) subunit of the 
pl-integrins, and the u-v (CD51) subunit of the 
vitronectin receptor (95,96). In addition, the cells are 
capable of inducing the class II MHC antigen (97,98) 
as well as the a-2-chain of the collagen receptor 
(CD49b) and the a-6-chain of the laminin receptor 
(CD49f) (99,100). 
Further, type II alveolar cells have also been 
shown to produce cytokines. Immunohistochemi- 
tally, type II cells obtained from patients with 
advanced idiopathic pulmonary fibrosis showed 
intense staining with anti-TGF-/I antibodies (101). 
Since TGF-P regulates cell growth and differenti- 
ation, as well as production of extracellular matrix 
proteins, this finding implicates the type II cell in the 
pathogenesis of fibrosing lung disease. Similarly, in 
pulmonary fibrosis, type II cells stain positive with a 
monoclonal antibody reactive to human TNF-a (102) 
which may also have a pathogenetic role in lung 
fibrosis. Moreover, adult rat type II pneumocytes 
have been demonstrated to express both epidermal 
growth factor (EGF) precursor mRNA and EGF 
protein (103). 
While these data suggest that type II pneumocytes 
may be able to produce cytokines, other studies 
demonstrate that these cells also respond to cytokine 
exposure. Type II cells induce class II MHC antigens 
in response to interferon-y (IFN-y) both in vitro and 
in viva (97,98). In addition, both IFN-y and IL-l/? 
induce significant quantities of nitric oxide (NO) 
from rat type II cells (104). Nitric oxide may play a 
role in the host defence against pathogens and in 
tissue damage associated with inflammation. Further, 
a recent study demonstrated that TNF-a inhibits 
phosphatidylcholine synthesis by human type II cells 
which is partially inhibited by prostaglandins (105). 
Finally, cultured rat type II cells have been shown to 
express binding sites for the epidermal growth factor 
(EGF), which is believed to promote lung maturation 
and reparation (103). 
Type II cells have also been shown to generate 
eicosanoids through both the cycle-oxygenase and 
the lipoxygenase pathways. The principal arachi- 
donic acid metabolites produced by isolated type II 
cells are prostaglandin (PG) E,, 6-keto-PGF,, (the 
stable degradation product of PGI,), thromboxane 
B,, and leukotrienes (LT) B, and C, (106-108). 
Prostaglandin E, and PGI, suppress various lym- 
phocyte, neutrophil, eosinophil and macrophage 
functions, including leukocyte mediator release 
(109) and modulate proliferation and extracellular 
matrix production by fibroblasts while throm- 
boxane and the leukotrienes have pro-inflammatory 
effects. 
Taken together, these findings support the view 
that type II pneumocytes participate in local immune 
and inflammatory responses via surfactant- 
independent pathways. This has, for instance, been 
shown for the down-regulation of lymphocyte profil- 
eration and DNA synthesis (110). More work is 
necessary to define the complex internet of 
surfactant-dependent and surfactant-independent 
immunoregulatory effects of this cell. 
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HUMAN SIJRFACTANT STUDIES 
Bronchoalveolar lavage (BAL) is the method of 
choice to study the surfactant system in man since it 
provides a low patient risk and gives access to all 
alveolar surfactant components. Nevertheless, this 
method has its drawbacks; e.g. the quantitation of 
the obtained epithelial lining fluid is limited by the 
complex nature of fluid dynamics during the pro- 
cedure (11 l-l 13). In addition, not all phospholipids 
in BAL fluid are necessarily surfactant phospho- 
lipids. Furthermore, the normal range of intra- and 
interindividual surfactant composition and quantity 
is, as yet, not known and could be intluenced by 
factors such as age or degree of physical fitness 
(114). Nonetheless, clinical studies have shown 
that quantitative changes of surfactant components 
in various lung diseases occur when compared 
to healthy controls. Normal values for SP-A in 
human BAL are usually within the range of 
0.5-55 pug ml - ’ lavage fluid (33,115-l 19). Depend- 
ing on the method employed, other authors (120) 
have described normal values of 6-26 lug ml- ‘. 
Similar to SP-A, SP-D has also been shown to be 
a good candidate for quantitation by ELISA 
techniques (121). 
The total phospholipid levels in BAL of healthy 
individuals seem to vary considerably among 
individuals and also among laboratories (e.g. 
116,122-127). Thus, the investigation of surfactant 
phospholipids by chromatographic determination of 
their relative distribution (e.g. 128) is more reliable. 
Another frequent approach is to determine the bio- 
physical properties (ability to lower surface tension) 
of the obtained materials (e.g. 129). 
Recently, Honda et al. (130) reported the aberrant 
occurrence of SP-A in sera of patients with idiopathic 
pulmonary fibrosis, alveolar proteinosis and, to a 
lesser extent, in patients with other pulmonary dis- 
orders like tuberculosis, pneumonia or emphysema. 
These findings probably reflect the injury of the 
alveolar-capillary border and may prove useful in the 
assessment of the severity and activity of various lung 
diseases. 
ADULT RESPIRATORY DISTRESS SYNDROME (ARDS) 
Certain conditions such as severe trauma, major 
surgical procedures, severe burns, sepsis, acute pan- 
creatitis, pneumonia and aspiration are capable of 
inducing an ARDS. Functionally, it may be defined 
as an acute, diffuse and severe disturbance of gas 
exchange at the alveolar-capillary border which 
may rapidly progress to respiratory failure. The 
diagnosis should be based on the following three 
criteria (131): 
(1) A ratio of the PaO, to the fraction of inspired 
oxygen (F,O,) 2 200; 
(2) Bilateral pulmonary infiltrates; and 
(3) A pulmonary artery wedge pressure < 18 mmHg 
or absence of clinical evidence of raised left atria1 
pressure. 
Adult respiratory distress syndrome is 
accompanied by increased alveolar permeability and 
pulmonary vascular resistance. Surfactant changes 
are thought to play an important role in the patho- 
genesis of this condition. However, it should be 
emphasized that ARDS represents a complex puzzle 
where surfactant is only one piece amongst many 
others. 
Serious disturbances of surfactant phospholipid 
composition and surfactant function, as well as 
reduced surfactant protein contents in BAL, have 
been described in animal models of ARDS (132-135) 
and in man (122,123,136140). 
One of the major mechanisms leading to surfac- 
tant disturbances in ARDS is probably a massive 
accumulation of fluid and protein in the alveolar 
compartment (141). The increased permeability of 
the alveolar-capillary barrier leads to non- 
cardiogenic pulmonary oedema with high alveolar 
concentrations of plasma-derived proteins. Oedema 
fluid and coagulated proteins block the alveolar air 
spaces and impair normal gas exchange. Several lines 
of evidence suggest that many of these plasma- 
derived proteins inactivate surfactant functions (141- 
143). This has been demonstrated experimentally for 
fibrinogen (144), fibrin monomer (145) albumin (146) 
and haemoglobin (147). Recently, Seeger et al. (148) 
have shown that surfactant phospholipids are incor- 
porated into polymerizing fibrin clots, a process 
which probably represents another major pathway of 
alveolar surfactant inactivation en route to ARDS. 
Yet another proposed mechanism is phospholipid 
degradation by phospholipases. These enzymes seem 
to be involved in the pathogenesis of at least some 
types of ARDS such as pancreatitis-, or sepsis- 
induced forms (140,149-152). Taken together, these 
data show that in ARDS, a major problem is not 
only an impaired alveolar type II cell function but 
also a relative deficit of functionally intact surfactant 
material due to massive inactivation processes. 
There is a general optimism that surfactant 
supplementation therapy might control or at least 
improve the surfactant dysfunctions in ARDS 
(139,140,153,154), although clinical evidence to sup- 
port this view is still limited and essentially only 
anecdotal (155-158). In a recently published trial 
(159), six patients were treated with a single intra- 
bronchial dose of 4 g (approximately 50-60 mg kg ~ ‘) 
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of a porcine surfactant preparation within the first 
2 days of onset of ARDS. The authors described a 
modest transient improvement in gas exchange, but 
no change in lung compliance or chest X-rays. Thus, 
the effects of this study were not impressive, but the 
chosen dose was very probably too low. Another 
recent preliminary communication (160) reports the 
effects of surfactant therapy in 51 patients with sepsis- 
induced ARDS within the first 18 h of onset of sepsis 
syndrome. A synthetic preparation (Exosurp) was 
aerosolized and administered continuously during 
inspiration for up to 5 days. The nebulized dose was 
approximately 44 mg of DPPC kg - ’ 24 h - ’ with a 
calculated pulmonary deposition of 2-5%. Thus, the 
effective dose was rather small. The authors described 
a dose-dependent trend in reduction of mortality. 
However, the therapy did not result in statistically 
significant improvements in their patients. 
In the near future, the results of other trials with 
porcine or bovine surfactants in higher effective doses 
should be published which are more likely to show 
significant beneficial effects. 
Nevertheless, there are numerous factors requiring 
further investigation in the development of optimal 
surfactant treatment strategies for patients with 
ARDS. Such factors include the ideal timing for 
surfactant administration, the best delivery tech- 
niques, the best possible surfactant dose, and the 
optimal preparation. Other issues include the poss- 
ible role of lung lavage prior to surfactant instillation 
to clear the alveolar space for surfactant inhibitors 
(139, or the potential benefit of administering 
phospholipase inhibitors along with the surfactant 
preparation. 
With regard to the best surfactant dose in ARDS, 
high dose therapies (300 mg kg- ’ or more) given 
intrabronchially will probably prove most successful 
to effectively over-ride the activity of alveolar sur- 
factant inhibitors. The most stable and effective 
preparation will very probably not only contain 
phospholipids but also surfactant specific proteins. 
There is substantial evidence to support the imple- 
mentation of surfactant therapy as early as possible 
in the course of the lung injury. Early markers 
which may be used in the future to indicate the need 
for exogenous surfactant could include SP-A and 
the ratio of small to large surfactant aggregates 
(i.e. poorly vs. normally functioning forms) in BAL 
fluids (134). 
The intelligent use of surfactant replacement 
therapy should improve survival rates in ARDS. 
However, a significant mortality will remain since the 
cause of death in ARDS is not always related to 
respiratory failure. At present, there is no sufficient 
evidence to support surfactant therapy in ARDS 
outside of controlled trials. 
PNEUMONIA 
In view of the effects of surfactant components in 
local host defence functions, it seems worthwhile to 
explore the potential role of the surfactant system in 
pneumonia. Surfactant disturbances might play a 
role in the pathogenesis of pneumonia and/or sur- 
factant changes could occur as a consequence of 
alveolar infection. Bacterial or viral invasion of the 
alveolar compartment probably induces local protein 
exudation and subsequent inhibition of surfactant 
functions similar to some of the events described in 
ARDS (see above) (161). Several studies have 
addressed these questions. 
In patients with bacterial pneumonia, a decrease in 
total surfactant lipids as well as decreases in PC and 
PG and changes in fatty acid composition of sur- 
factant phospholipids, have been reported (136,161). 
It is also known that surface tension of BAL fluids of 
such patients is increased. Further, Baughman et al. 
(120) recently reported altered SP-A levels in BAL 
fluids of 22 patients with bacterial pneumonia (12 
gram-positive and 10 gram-negative). The concen- 
trations of SP-A in BAL fluids were clearly and 
significantly decreased in both pneumonia groups in 
comparison to 11 healthy controls, with particularly 
low levels in the gram-positive group. Less evidence 
exists regarding the effects of viral pneumonias on the 
surfactant system, but it has been postulated that 
viruses could injure and destroy alveolar type II cells, 
thus interfering with surfactant synthesis and secre- 
tion (161). 
A number of investigators have looked into sur- 
factant changes associated with P. carinii pneumonia 
(PCP). In animal models, SP-A levels, unlike phos- 
pholipids, are increased in this type of infection (32). 
In 22 patients with AIDS-related pneumonia (mainly 
PCP), a marked increase of SP-A in BAL was also 
reported (117). However, it remained unclear 
whether the observed changes were primarily related 
to HIV infection or to pneumonia. Indeed, other 
investigators (33) found elevated SP-A levels in HIV- 
infected individuals without PCP or evidence of other 
current pulmonary infections. According to two 
other human studies, the BAL phospholipid content 
is reduced in HIV-positive patients with PCP, 
whereas phospholipase A, activity is increased 
(162,163). However, reduced phospholipid levels 
have also been described in HIV-positive patients 
without evidence of PCP or other infections (164). 
Thus, currently available evidence suggests that HIV- 
infected individuals, both with or without PCP, have 
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raised SP-A levels while phospholipid concentrations 
are decreased. Further studies are necessary to con- 
firm and explain this seemingly unique phenomenon. 
Interestingly, a 120 kDa glycoprotein covering the 
surface of freshly isolated P. carinii has been ident- 
ified which is a ligand for the carbohydrate-binding 
domain of SP-A (31). The SP-A binding capacity of 
P. carinii may interfere with the recognition and 
phagocytosis of this micro-organism by alveolar 
macrophages which normally utilize this ligand (32). 
These findings suggest that increased SP-A levels in 
HIV-positive individuals may have detrimental 
effects on the local defence mechanisms, and raise 
speculations about whether P. carinii is able to utilize 
this phenomenon for its own protection. Another 
recent report (165) has shown that SP-D also binds to 
P. carinii in a rat model of PCP in vivo and augments 
the binding of P. carinii to alveolar macrophages. 
However, this process did not significantly influence 
the phagocytosis of the micro-organisms. 
Studies in animal models (161,166) have shown 
beneficial effects of surfactant substitution therapy in 
viral pneumonia and PCP. In a recent case report 
(167), selective intralobar instillation of a bovine 
surfactant preparation led to improved gas exchange 
and ventilator settings in a patient with severe bac- 
terial pneumonia, although the chosen dose was 
surprisingly low (240 mg). Taken together, presently 
available evidence suggests that it may be rational to 
treat severe pulmonary infections with exogenous 
surfactant (161). Controlled trials should clarify this 
issue as soon as surfactant preparations are available 
at lower costs. 
SARCOIDOSIS 
Sarcoidosis is a generalized granulomatous disease 
of unknown origin frequently involving the lung. 
Bronchoalveolar lavage phospholipid levels in sar- 
coidosis are not significantly altered in comparison 
with healthy individuals, and there is no clear confir- 
mation of changes in the phospholipid profile 
(1 l&126,127,168). Thus, presently available data 
suggest that phospholipid analysis of BAL fluids 
is only of limited scientific and clinical value in 
sarcoidosis. In a recently published study of 35 
patients with active, untreated type I and type II 
sarcoidosis, the authors’ group found significantly 
elevated SP-A levels (mean 8.0 pug ml - ‘) in compari- 
son to healthy controls (mean 4.0 ,ug ml ~ ‘) (119). 
Another recent study (118) found only a slight, but 
not significant, increase of SP-A in 20 untreated 
sarcoidosis patients compared to healthy controls. 
The differences of these two studies are difficult to 
interpret, since no information on disease activity, 
BAL lymphocyte percentage or disease stage is given 
in the latter publication. In sarcoid alveolitis, not 
only T-lymphocytes but also alveolar macrophages 
are activated (169). Both cell populations are 
involved in the formation of the characteristic non- 
caseating granuloma, and it may be speculated that 
enhanced alveolar SP-A secretion could contribute to 
macrophage activation in this disease. Further stud- 
ies are necessary to confirm surfactant changes in 
pulmonary sarcoidosis and to evaluate their role and 
potential usefulness in the differential diagnosis of 
fibrosing lung disorders. 
HYPERSENSITIVITY PNEUMONITIS (HP) 
The immunoregulatory functions of surfactant 
make this pulmonary disease an interesting object for 
carrying out surfactant studies. However, only a few 
reports have so far addressed the role of surfactant 
in HP. In a recent study by the authors’ group, BAL 
fluids of 10 patients with untreated, active HP 
showed significantly higher SP-A values (mean 
9 pg ml ~ ‘) than controls (mean 4pg ml - ‘) (119). 
Immunocytochemical evidence of elevated SP-A con- 
tents in alveolar macrophages of such patients were 
also found (170). 
Another study demonstrated that acute immune 
lung injury in guinea pigs is augmented in animals 
with partial surfactant depletion, while surfactant 
replacement ameliorated the parameters of lung 
injury (171). This prompted a somewhat optimistic 
comment that surfactant replacement might be useful 
as a therapy of cell-mediated immune diseases of the 
lung (172). Further work is necessary to understand 
more clearly the role of surfactant in this type of 
lymphocytic alveolitis. 
IDIOPATHIC PULMONARY FIBROSIS (IPF) 
Idiopathic pulmonary fibrosis is a progressive 
fibrosing lung disease of unknown origin which 
involves alveolar epithelial injury and alveolar type II 
cell proliferation (173). In 32 patients with untreated 
IPF, PG was lowered and an increase of PG after 
commencement of steroid therapy seemed to indicate 
clinical improvement (125). In another study (126), 
total phospholipid concentrations in BAL were 
reduced with decreased amounts of PG and DPPC 
and an increase in PI. Robinson et al. (127) reported 
similar findings in 15 untreated patients. Total phos- 
pholipid levels in BAL were less than half of controls 
with raised percentages of PI and lowered PG. The 
severity of these changes correlated with more 
advanced histopathologic fibrosis. In 28 patients 
(including the 15 patients from the former study), the 
SP-A content of BAL was reported to be significantly 
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lower than in normal controls (116). By contrast, 
another study (120) found similar SP-A levels in the 
BAL fluids of 11 IPF patients and 10 controls (means 
18.4 pg ml - i vs. 15 pug ml ~ ‘, respectively). Thus, 
further work needs to be done to clarify surfactant 
changes in IPF. Interestingly, Honda et al. (130) 
recently described the aberrant appearance of SP-A 
in sera of IPF patients. This finding is not diagnostic 
(see ‘Human surfactant studies’), but it probably 
reflects severe damage of the alveolar-capillary 
border and might be clinically useful for assessing 
disease activity. 
ALVEOLAR PROTEINOSIS (AP) 
This is a rare disorder of the alveolar type II cell 
which is characterized by excessive synthesis and 
secretion of abnormal surfactant material. A typical 
finding is accumulation of abnormal multilamellated 
structures in the alveoli (174). Bronchoalveolar 
lavage fluid contains increased total phospholipids 
with a relative decrease in PG and an increase in 
PI (124). The diagnosis is conventionally made on 
histologic grounds. Recently, it has been shown that 
this disease may also be confirmed by high SP-A 
levels in BAL fluids (in the range of 20-60 pug ml - ‘) 
(175) or in sputum (176). Also, SP-A may be found in 
the sera of such patients, although this is not diag- 
nostic for AP since patients with idiopathic pulmo- 
nary fibrosis and certain other lung diseases may also 
show this phenomenon (130). Alveolar proteinosis 
possibly comprises several forms of different type II 
cell disorders, since it has recently been shown that 
AP may occur not only as an apparently acquired 
disease in adulthood, but also as a congenital dis- 
order in full-term newborns (44,177). The latter 
causes respiratory failure and often leads to death 
in infancy. The underlying defect is an inherited 
deficiency of SP-B, which emphasizes the importance 
of this protein for normal surfactant function. 
Further, it has been shown that this SP-B deficiency 
is associated with the aberrant processing and secre- 
tion of an immature SP-C peptide (178). The therapy 
of the adult form of AP consists of repeated whole 
lung lavage to clear the lungs of the accumulated 
abnormal surfactant products. In the congenital 
form, present hopes centre around gene therapy. 
LUNG TRANSPLANTS 
One of the first studies that investigated possible 
surfactant abnormalities in lung transplants was car- 
ried out in excised dog lungs during hypothermic 
storage (4°C for 24 h) and after left lung transplan- 
tation (six dogs, 24 h postoperative observation 
period) (179). A decrease of dipalmitoyl- 
phosphatidylcholine (DPPC) levels in BAL fluids was 
found in both situations. The authors concluded that 
their findings reflected ischaemic damage to alveolar 
type II cells. However, analysis of other BAL phos- 
pholipids and surfactant specific proteins was not 
performed. Another, more recent, study (180) inves- 
tigated the effects of lung transplantation on the 
integrity of the surfactant system in dogs after 2 or 
12 h ischaemic time plus 6 h of reperfusion. In trans- 
plants with 12 h of ischaemia, gas exchange was 
impaired, total serum proteins in BAL were 
increased, and the PG and SP-A content in large 
surfactant aggregates were decreased. Thus, pro- 
longed storage of the donor lung before transplan- 
tation led to (presumably ischaemic) disturbances of 
surfactant composition and to alveolar accumulation 
of potential surfactant inhibiting proteins. The 
authors concluded that surfactant supplementation 
should be investigated in lung transplantation. 
Another recent study by the same group (181) 
tested the effects of surfactant replacement therapy 
immediately before reperfusion in canine single lung 
transplants after prolonged storage times (37-38 h). 
Six hours after reperfusion, three out of eight dogs 
had nearly normal lung function while five did not 
respond, compared to a group of control animals. It 
was concluded that surfactant therapy can result in 
excellent preservation of lung grafts, but further 
investigations are required to determine the factors 
responsible for this differential response. The expla- 
nation for these observations may be two-fold: First, 
the chosen surfactant dose (50 mg kg- ‘) was com- 
paratively low; and second, the substitution therapy 
may have come too late. The latter argument is 
supported by the view that the duration of graft 
ischaemia is mainly responsible for the persistent 
type II cell malfunction. 
A further recent study (182) in rat lung transplants 
revealed that longer ischaemic times caused a 
more severe re-implantation response in the grafts 
as shown by higher alveolar concentrations of 
surfactant-inhibiting proteins and relative decreases 
of phosphatidylcholine. Preliminary data from the 
authors’ group (183) demonstrate a highly significant 
reduction of mean SP-A levels in BAL fluids from 
lung transplant recipients compared to normal con- 
trols [transplant patients (n= 3 1): 0.87 lug ml - ‘; con- 
trols (n=21): 4.0,ug ml- i, P<O.OOOl]. There was no 
correlation of SP-A levels to the time after 
transplantation or to lung function parameters. 
Taken together, these studies suggest a persistent 
type II cell malfunction after lung transplantation, 
which is most probably related to the ischaemia time 
between organ explantation and implantation/ 
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reperfusion. Surfactant replacement therapy of 
explanted organs may possibly conserve type II pneu- 
mocyte function, perhaps by reducing the metabolic 
activity of these cells by way of feedback inhibition to 
levels that allow their functional survival throughout 
the ischaemic phase. Clinical studies on these pro- 
posed effects of surfactant supplementation in donor 
lungs are needed to clarify this issue and are presently 
initiated in several institutions. 
OBSTRUCTIVE LUNG DISEASES 
As mentioned above, surfactant is not only synthe- 
sized in the alveolar region but also, albeit to a lesser 
extent, in the peripheral airways (see ‘Morphological 
and ultrastructural aspects’). Furthermore, the air- 
ways are supplied by alveolar surfactant components 
via the mucociliary escalator. Theoretical consider- 
ations and experimental evidence suggest that 
surfactant may help to maintain the openness of 
peripheral conducting airways (e.g. 184,185). 
Obstructive lung diseases are characterized by 
smooth muscle contraction, enhanced mucus secre- 
tion, mucus plugging, oedema of airway walls, 
exudation of a proteinaceous fluid, and impaired 
mucociliary clearance (e.g. 186). Some of these 
processes may disturb proper surfactant function, 
e.g. exudated proteins may inhibit the surface activity 
and accumulated fluid and mucus may dilute and 
alter the normal surfactant layer. Therefore, patho- 
logical processes in obstructive lung diseases are 
likely to interfere with putative surfactant functions 
in peripheral airways. 
Several years ago, a preliminary report by 
Lachmann et al. described the inhibition of allergic 
bronchoconstriction in guinea pigs after intrabron- 
chial surfactant instillation (187). Kurashima et al. 
(188) conducted a double-blind, placebo-controlled 
trial in 11 patients who inhaled an aerosolized sur- 
factant preparation (10 mg, 5 min, inhalation time) 
during acute asthma attacks. The authors described 
improved FEV,, FVC and arterial PO,-values in the 
treatment group. Hohlfeld et al. (189,190) reported 
the inhibition of acetylcholine-induced bronchocon- 
striction after inhalation of aerosolized surfactant in 
rats. Simultaneous inhalation of a &adrenoreceptor 
agonist had no additive effect. Recently, van de 
Graaf et al. (118) found decreased SP-A levels in 
BAL fluids of 12 asthmatics in comparison with 
healthy controls. However, phosphatidylcholine 
levels were not significantly altered. Larger studies 
are needed to substantiate such changes of the 
surfactant system in obstructive lung diseases. 
Taken together, these data suggest that surfac- 
tant disturbances may play a role in obstructive 
pulmonary disorders, and surfactant therapies 
might be able to prevent or even antagonize 
bronchoconstriction. 
RADIATION PNEUMONITIS 
Radiation pneumonitis and subsequent fibrosis are 
well-known complications after radiotherapy of 
thoracic organs. Animal studies have shown that the 
number of lamellar bodies in type II cells drops 
dramatically immediately after radiation, and that this 
is accompanied by a transient increase in lavage 
surfactant content (191). In vitro studies by the same 
group demonstrated that this is a direct effect of 
radiation on type II cells. In four patients who under- 
went hemithorax irradiation for mesothelioma (115), 
protracted alveolar accumulation of surfactant- 
inhibiting proteins, and decreased PG-, PI, PC- and 
SP-A-concentrations were observed in the alveolar 
lining fluid. Thus, radiation may cause surfactant dis- 
turbances by at least two mechanisms. First, it leads to 
alveolar accumulation of surfactant inhibitors by 
unspecific injury of the alveolar wall; and second, it 
specifically injures type II cell function. A further 
mechanism may involve a switch from surfactant 
phospholipid synthesis to cell membrane repair. 
DRUG-INDUCED PULMONARY DISEASE (DIPD) 
Drug-induced pulmonary disease is often 
accompanied by histological changes of alveolar type 
II cells like dysplasia and proliferation (192,193). 
Therefore, one might expect changes of type II cell 
surfactant production in drug-induced lung injury. 
Bleomycin is an anti-neoplastic drug which has a 
known capability to induce fibrosing lung disease 
(192). In animals (194196), bleomycin apparently 
leads to decreased total phospholipid concentrations 
within the first days of lung injury followed by 
an increase above normal values with a reduced 
PG:PI ratio. These changes are accompanied by a 
deterioration of lung function parameters. 
Amphiphilic drugs like amiodarone, propranolol, 
chloramphenicol and chlorpromazine may interact 
with pulmonary phospholipid metabolism. A pro- 
posed mechanism for the pulmonary toxicity of 
amiodarone is that normal phospholipid degradation 
is impaired, probably by inhibition of phospholipases 
(197,198). This leads to growing alveolar and type II 
cell surfactant pools (199), a phenomenon which is 
called pulmonary phospholipidosis. It can eventually 
lead to progressive respiratory failure. 
SURF’ACTANT REPLACEMENT THERAPY 
A number of surfactant preparations are now in 
use (Table 2) which are predominantly marketed for 
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Table 2 Commercially available surfactant preparations 
Natural surfactant extracts (Phospholipids plus SP-B and SP-C) 
Alveofact@ Thomae/Boehringer Ingelheim Co., Germany Bovine 
Survanta@ Abbott Co., U.S.A. Bovine 
Surfactant-TAO Tokyo Tanabe Co., Japan Bovine 
Curosurp Chiesi Farmaceutici Co., Italy Porcine 
Synthetic surfactants (Phospholipids only) 
ALE@ Britannia Pharmaceuticals Co., U.K. DPPC+PG (7:3) 
Exosurp Burroughs Wellcome Co., U.S.A. DPPC f Hexadecanol +Tyloxapol 
SP, surfactant protein; DPPC, dipalmitoyl-phosphatidylcholine; PG, phosphatidylglycerin. 
the treatment of IRDS. The composition and prop- 
erties of these preparations vary and it is not yet clear 
which one of them should be preferred with regard to 
efficacy, safety, availability and cost. 
Natural surfactant extracts 
Bovine surfactant preparations [e.g. Alveofac@ 
(Thomae/Boehringer Ingelheim, Germany), Survantaa 
(Abbott, U.S.A.) and Surfactant-TAD (Tokyo 
Tanabe, Japan)] are organic-solvent extracts of cow 
lungs. They contain phospholipids plus SP-B and 
SP-C, but no SP-A or SP-D. 
Porcine surfactants [e.g. Curosurp (Chiesi 
Farmaceutici, Italy)] are organic-solvent extracts 
from porcine lungs with a composition comparable 
to bovine surfactant preparations. 
Natural surfactants from amnion fluid or BAL 
have also been used. A serious drawback of all 
natural surfactants is their high cost. 
Synthetic surfactants 
ALEC@ (Britannia Pharmaceuticals, U.K.) is a 
simple preparation of only two phospholipids, DPPC 
and PG, in weight proportion of 113. 
Exosurp (Burroughs Wellcome, U.S.A.) is a 
mixture of DPPC, hexadecanol, and tyloxapol. 
It is not yet clear if recombinant surfactant pro- 
teins or perhaps polypeptides with their essential 
functions will be used in future surfactant prepar- 
ations. Certainly, such fully-synthetic surfactants 
would guarantee a high quality and nearly unlimited 
availability. 
Dosage 
Most data on surfactant dosage in adults are 
derived from animal studies or clinical trial in IRDS. 
It is probably necessary to choose higher relative 
surfactant doses in the treatment of ARDS, since 
surfactant inhibitors are present in addition to the 
existing surfactant deficit. An adequate single rec- 
ommended dose for the treatment of ARDS is 
50-300 mg phospholipids kg ~ i body weight 
(6,143,156,200), but the optimal dose may well turn 
out to be even higher. 
Potential side-efsects 
Surfactant preparations containing foreign pro- 
teins should be expected to be a potential source of 
sensitization. Data from children with IRDS show 
frequent occurrence of circulating surfactant-anti- 
surfactant immune complexes even before com- 
mencement of surfactant supplementation (201,202). 
The levels of these immune complexes correlate with 
subsequent development of bronchopulmonary dys- 
plasia (203), and probably reflect the extent of the 
lung injury. In fact, antibodies against surfactant 
proteins have been shown to decrease after surfactant 
treatment (204). The authors are not aware of any 
report in the literature on immunological or other 
serious side-effects of surfactant treatment. In conclu- 
sion, the existing clinical experience suggests that 
surfactant substitution therapy is not associated with 
serious risks. 
Conclusions 
Surfactant research in recent years has supplied us 
with extensive information on the composition of 
pulmonary surfactant and its various functions. It 
will be the task of pulmonary medicine in the forth- 
coming years to make use of this information by 
investigating the clinical relevance of surfactant prob- 
lems in various lung diseases, and by introducing 
surfactant studies and therapies into clinical practice 
where appropriate for the benefit of patients. 
In the future, surfactant analyses will not be used 
primarily to arrive at a specific diagnosis of a disease, 
with the exception of a few disorders like alveolar 
proteinosis. However, present evidence suggests that 
surfactant studies can provide information about 
the activity and severity of a variety of respiratory 
conditions. Furthermore, they can be used to predict 
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and monitor the potential benefit of surfactant 
substitution therapy. 
Therapeutic perspectives are currently focused on 
ARDS. Here, further results of clinical trials are 
awaited with interest. Other indications of surfactant 
therapy may comprise severe pneumonia, lung trans- 
plant recipients and severe, acute episodes of obstruc- 
tive lung diseases. The role of the surfactant system in 
pulmonary host defence mechanisms and local 
immunomodulation will continue to stimulate 
clinical interest in its role in inflammatory and 
immunologic disorders of the lung. 
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